TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03099070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress
Description: Trier Social Stress Test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress
Description: Trier Social Stress Test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: 12-hour fasting prior to study visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: 12-hour fasting prior to study visit
Study: NCT00938964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine versus placebo infusion for 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lidocaine versus placebo infusion for 48 hours
Study: NCT02070471

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC28-0126 Dose A
Description: LC28-0126 Dose A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC28-0126 Dose B
Description: LC28-0126 Dose B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC28-0126 Dose C
Description: LC28-0126 Dose C
Study: NCT02436655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical aortic valve replacement
Description: open heart aortic valve replacement
Study: NCT03699384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: AZA 75 mg/m\^2 SC or IV D 1-7 28 day cycle x 1
Study: NCT01423890

Intervention type: GENETIC
Group type: OTHER
Intervention: ONCOTYPEDX Test
Description: Gene signature test containing 21 genes (16 cancer-related genes, e.g., invasion, proliferation, ER, Her 2 and five reference genes) and generates an individualized recurrence score.
Study: NCT04380025

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Oral Mirtogenol
Description: The experimental arm is Oral Mirtogenol dietary supplement, one capsule daily in addition to bimatoprost ophthalmic drops with primary open angle glaucoma
Study: NCT03699384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10mg/kg IV D1, D15, 28d cycle Until progression or MRD If MRD-, tx x 1 yr or go to allo SCT
Study: NCT04452929

Intervention type: DRUG
Group type: OTHER
Intervention: Erenumab
Description: Subcutaneous injection of 140 mg erenumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab
Description: Subcutaneous injection of 140 mg erenumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of saline placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitonin gene-related peptide
Description: Intravenous infusion of 1.5ug/min calcitonin gene-related peptide over 20 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcitonin gene-related peptide
Description: Intravenous infusion of 1.5ug/min calcitonin gene-related peptide over 20 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Oral intake of 200 mg cilostazol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cilostazol
Description: Oral intake of 200 mg cilostazol.
Study: NCT03891160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D model of heart
Description: To assess if a 3D printed cardiac model improves visualization of VAD and cannula placement sites in CHD-HF patients as compared to 2D imaging. The investigators will prospectively enroll CHD-HF patients at multiple centers and randomize to group A (3D printed models will be used for pre-VAD planning) or Group B (controls).
Study: NCT03654742

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tonsillectomy
Description: removal of tonsil tissue as described in the study arms
Study: NCT02724878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Study: NCT01175538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: In the Gp-L group, patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day
Study: NCT04380025

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of oral Dietary supplement
Description: This is the oral placebo of the supplement (control) un daily capsule in addition to the bimatoprost ophtalmic drops
Study: NCT01175538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: lactulose will be used in 30-60ml/day
Study: NCT02795572

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Vitamin B12 100 mcg oral once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: Omega-3 Fatty Acids 900 mg oral three times a day (600 mg EPA, 300 mg DHA)
Study: NCT03300011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: PTCA or PCI
Study: NCT02632968

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pinhole surgery with and without buttons

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pinhole surgery with and without buttons
Study: NCT01920334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem CR 12.5mg
Description: Patients will be given zolpidem CR 12.5mg each night for, at least, 3 consecutive nights, including the first night on the Cardiac ICU, when the undergo a full-night polysomnography

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo pills at night, according to their usual sleep time, from the first night on the Cardiac ICU, until their hospital discharge
Study: NCT03849547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App Balance training
Description: Training specially designed for balance ability of chronic ankle instability groups.~Guidance through smartphone application as home program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Balance training
Description: Training specially designed for balance ability of chronic ankle instability groups.~Follow the usual home program provided in clinics.
Study: NCT01442376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Single dose Palonosetron IV 10 mcg/kg up to a maximum total dose of 0.75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Single dose Palonosetron IV 20 mcg/kg up to a maximum total dose of 1.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Single three (every 4 hours) Ondansetron IV doses 0.15 mg/kg up to a maximum total dose of 32 mg
Study: NCT02841631

Intervention type: GENETIC
Intervention: HPV status and typing of tissue
Description: HPV status and typing of tissue
Study: NCT03193385

Intervention type: PROCEDURE
Intervention: closed reduction
Description: Closed reduction is where the thigh bone is placed into the socket without any surgical incision being made. This is more likely to be performed in a child under the age of four year. The femoral head is gently manipulated into the socket, whilst the child is under anaesthetic. Once the femoral head is in place, a hip Spica is applied and can remain in place for up to three months to maintain the hip in the correct position. This allows time for healing and for the socket and the thigh bone to mould together as a joint.
Study: NCT01657942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate MR Guided Focused Ultrasound
Description: ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
Study: NCT01442376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ondansetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ondansetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Palonosetron
Study: NCT00989950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daytrana
Description: Daytrana patch 10-30 mg administered once daily for 9hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daytrana
Description: Daytrana 10-30 mg worn once daily for 10 hr wear

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daytrana
Description: Daytrana 10-30 mg worn once daily for 11 hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daytrana
Description: Daytrana 10-30 mg worn once daily for 12 hrs
Study: NCT02672267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cells
Description: human Allogeneic Low Oxygen mesenchymal stem cells; Ischemia tolerant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactated Ringer's Solution
Study: NCT01674387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: 56 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral Jiaji (EX-B2) of cervical positive reaction plane (taking two pairs). Besides, bilateral Jianzhongshu (SI15) and bilateral Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.

Intervention type: OTHER
Group type: OTHER
Intervention: comprehensive treatment
Description: Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
Study: NCT02325180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Study: NCT02333123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Each 300mg aspirin capsule will contain over-encapsulated 4 x Aspirin 75mg tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Aspirin)
Description: Each placebo capsule will contain a lactose and magnesium stearate blend, and will appear identical in weight, colour and size to the matched aspirin capsules.
Study: NCT03453554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Notebook app
Description: Training in use of Digital Memory Notebook app

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Notebook app
Description: Training in use of Digital Memory Notebook app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Home Prompting
Description: Smart-home sensor based activity-aware prompting to support digital memory notebook app use
Study: NCT01150422

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alternative follow-up
Description: After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist. Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned data two weeks after mifepristone administration. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests. Provider will review the women's responses to the checklist and confirm whether, based on the woman's responses, she should return for a follow up visit. During the follow-up phone call, women will also be asked about the satisfaction and acceptability of the alternative follow-up procedure.
Study: NCT00945490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1207
Description: Single intraprostatic injection of 2.5 mg NX-1207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intraprostatic injection of placebo
Study: NCT02659462

Intervention type: OTHER
Intervention: Cardio Pulmonary Exercise Testing
Description: Cardio Pulmonary Exercise Testing

Intervention type: OTHER
Intervention: Cardio Pulmonary Exercise Testing
Description: Cardio Pulmonary Exercise Testing

Intervention type: OTHER
Intervention: Cardio Pulmonary Exercise Testing
Description: Cardio Pulmonary Exercise Testing
Study: NCT01441349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IP chemotherapy
Description: Irinotecan/cisplatin (IP) chemotherapy~* Cisplatin(30 mg/m2) diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8.~* Irinotecan(65mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1 \& 8~* Every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP chemotherapy plus simvastatin
Description: * Cisplatin(30mg/m2)diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8~* Irinotecan( 65 mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1\& 8.~* Every 21days.~* Simvastatin 40 mg per day orally D1of cycle 1
Study: NCT03157115

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinocardiography
Description: This device records the electric and mechanic function of the heart. With electrodes and adequate electronics, ECG is recorded. 6 degrees of freedom accelerometers are also included in the device to measure the micro accelerations of the body at the body surface when the device is placed on the skin. Using physics principles and adequate calibration, those accelerations allow us to calculate parameters such as kinetics energies related to cardiac contractility.~During a standard echocardiography appointment for a patient suffering from a cardiovascular condition with/without heart failure, the cardiologist will monitor the heart of the patient with the Kino device (examination lasting a few minutes with the patient lying down on a bed). Data will be matched between the control group and the experimental group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinocardiography
Description: This device records the electric and mechanic function of the heart. With electrodes and adequate electronics, ECG is recorded. 6 degrees of freedom accelerometers are also included in the device to measure the micro accelerations of the body at the body surface when the device is placed on the skin. Using physics principles and adequate calibration, those accelerations allow us to calculate parameters such as kinetics energies related to cardiac contractility.~During a standard echocardiography appointment for a patient suffering from a cardiovascular condition with/without heart failure, the cardiologist will monitor the heart of the patient with the Kino device (examination lasting a few minutes with the patient lying down on a bed). Data will be matched between the control group and the experimental group.
Study: NCT03053856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Adjuvant pembrolizumab 200 mg every 3 weeks for up to 24 months. (treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curative resection
Description: Neoadjuvant concurrent chemoradiotherapy followed by curative resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant concurrent chemoradiotherapy
Description: RT 44 Gy/22 Fractions for 5 weeks With Chemotherapy (Cisplatin 25mg/m2 once weekly, Paclitaxel 50mg/m2 once weekly)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2 once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50mg/m2 once weekly
Study: NCT04695041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050/ Placebo
Description: Participants receive either 800mg PBI-4050 capsules or placebo, twice a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050/ Placebo
Description: Participants receive either 800mg PBI-4050 capsules or placebo, twice a day for 14 days
Study: NCT03976323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablets
Study: NCT01475292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV568
Description: RV568 100 ug administered via a nebuliser once daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via a nebuliser once daily for 14 days
Study: NCT04211324

Intervention type: DEVICE
Intervention: TENS
Description: Volunteers in this group (n=50) will receive only one session of 5-minute extra-oral TENS applied on bilateral parotid gland with 50 HZ frequency and pulse duration 250 µs.

Intervention type: DEVICE
Intervention: electro-acupuncture
Description: Volunteers in this group (n=50) will receive only one session of 5-minute electro-acupuncture on local acu-points St4 and St 7 bilateraly with 2 HZ frequency.
Study: NCT02827552

Intervention type: OTHER
Group type: OTHER
Intervention: skin biopsy
Description: skin biopsy performed prior radiation to characterize in blind the individual radiosensitivity of the patient
Study: NCT03690258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Variable load exercise
Description: This study is being conducted to determine whether variable load training approach (nHANCE™ squat - more data available at http://nhance.se/) is an effective countermeasure to attenuate for rapid declines in muscle power, function, that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, safety guidelines and protocols could be developed aimed at reducing health risks in seniors. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Variable load exercise
Description: This study is being conducted to determine whether variable load training approach (nHANCE™ squat - more data available at http://nhance.se/) is an effective countermeasure to attenuate for rapid declines in muscle power, function, that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, safety guidelines and protocols could be developed aimed at reducing health risks in seniors. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system.
Study: NCT01915875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sophrology sessions at home
Description: The sophrology is a dynamic method of physical and psychical relaxation
Study: NCT02749721

Intervention type: DRUG
Group type: OTHER
Intervention: vortioxetine
Description: Open-label vortioxetine
Study: NCT00312377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: oral
Study: NCT01085929

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Drainage
Description: Surgical incision of the skin surface followed by expression of purulence with or without debridement or manual exploration of abscess cavity.
Study: NCT04319198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hiy
Description: Administered intravenously
Study: NCT03654742

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tonsillectomy
Description: removal of tonsil tissue as described in the study arms

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tonsillectomy
Description: removal of tonsil tissue as described in the study arms
Study: NCT02160483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging
Description: 3 Tesla magnetic resonance imaging
Study: NCT01285960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Treatment UF V2
Description: Treatment with the ExAblate UF V2 system. Patients may have up to two ExAblate treatments within a two-week period.
Study: NCT00473746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: The first cohort was a abiraterone acetate 250 mg/day orally (by mouth), once daily for 28-day treatment periods , if no dose limiting toxicity (DLT) was documented at this dose, the dose will be escalated to next dose levels 500, 750, and 1000 mg/day. The dose escalation will continue to a maximum of 1000mg/day until Maximum Tolerated Dose (MTD) and a recommended Phase II dose was established.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000 mg daily under fasted conditions upto 10 cycles of therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone/prednisolone or dexamethasone
Description: prednisone/prednisolone (5 mg twice daily) or dexamethasone (0.5 mg once daily) concurrent with abiraterone acetate
Study: NCT00667420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab, epirubicin, oxaliplatin, xeloda
Description: pilot study
Study: NCT04695041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050/ Placebo
Description: Participants receive either 1200mg PBI-4050 capsules or placebo, once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050/ Placebo
Description: Participants receive either 1000 mg PBI-4050 capsules or placebo, twice a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050/ Placebo
Description: Participants receive either 1200 mg PBI-4050 capsules or placebo, twice a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050/ Placebo
Description: Participants receive either 800 mg PBI-4050 capsules or placebo, three times a day for 14 days
Study: NCT03331458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exrecise intervention
Description: Subjects will undergo pre-intervention measures, complete a daily physical activity diary, and post-intervention measures